Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy

Samantha M. Sarrett, Outi Keinänen, Eric J. Dayts, Guillaume Dewaele-Le Roi, Cindy Rodriguez, Kathryn E. Carnazza, Brian M. Zeglis

Published: 2021-06-13 DOI: 10.1038/s41596-021-00540-2

PET imaging

radioimmunotherapy

pretargeting

Diels–Alder reaction

cancer therapy

AI 解读

Supplementary information

Supplementary Information

Supplementary Methods.

Generation of mouse–human chimeric embryos

Genome-wide quantification of transcription factor binding at single-DNA-molecule resolution using methyl-transferase footprinting

Generation of CRISPR–Cas9-mediated genetic knockout human intestinal tissue–derived enteroid lines by lentivirus transduction and single-cell cloning

A puromycin-dependent activity-based sensing probe for histochemical staining of hydrogen peroxide in cells and animal tissues

Decoding personal biotic and abiotic airborne exposome

A clinically relevant model of focal embolic cerebral ischemia by thrombus and thrombolysis in rhesus monkeys

Bioengineering human intestinal mucosal grafts using patient-derived organoids, fibroblasts and scaffolds

Biomimetic tail-to-head terpene cyclizations using the resorcin[4]arene capsule catalyst

Neuroscience robotics for controlled induction and real-time assessment of hallucinations

Scanorama: integrating large and diverse single-cell transcriptomic datasets

Single-cell RNA sequencing (scRNA-seq)（单细胞RNA测序）

Data integration（数据集成）

Heterogeneity（异质性）

查看全部

Sections

Figures

References

Supplementary information

Deri, M. A., Zeglis, B. M., Francesconi, L. C. & Lewis, J. S. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl. Med. Biol. 40, 3–14 (2013).
Verel, I. et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm. 18, 655–661 (2003).
Stillebroer, A. B. et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 64, 478–485 (2013).
Kramer, K. et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-ommaya 131-I-3F8. J. Clin. Oncol. 25, 5465–5470 (2007).
Zeglis, B. M., Houghton, J. L., Evans, M. J., Viola-Villegas, N. & Lewis, J. S. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg. Chem. 53, 1880–1899 (2014).
Kramer, K. et al. A phase II study of radioimmunotherapy with intraventricular 131I-3F8 for medulloblastoma. Pediatr. Blood Cancer 65, 10.1002/pbc.26754 (2018).
van Loon, J. et al. PET imaging of zirconium-89 labelled cetuximab: a phase I trial in patients with head and neck and lung cancer. Radiother. Oncol. 122, 267–273 (2017).
Pandit-Taskar, N. et al. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin. Cancer Res. 21, 5277–5285 (2015).
Maloney, R., Buuh, Z. Y., Zhao, Y. & Wang, R. E. Site-specific antibody fragment conjugates for targeted imaging. Methods Enzymol. 638, 295–320 (2020).
Jain, M., Venkatraman, G. & Batra, S. K. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin. Cancer Res. 13, 1374–1382 (2007).
Hnatowich, D. J., Virzi, F. & Rusckowski, M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28, 1294–1302 (1987).
Leonidova, A. et al. In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system. Chem. Sci. 6, 5601–5616 (2015).
Salaun, P. Y. et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J. Nucl. Med. 53, 1185–1192 (2012).
Rondon, A. & Degoul, F. Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy. Bioconjug. Chem. 31, 159–173 (2020).
Reiner, T. & Zeglis, B. M. The inverse electron demand Diels–Alder click reaction in radiochemistry. J. Label. Comp. Radiopharm. 57, 285–290 (2014).
Keinänen, O. et al. Dual radionuclide theranostic pretargeting. Mol. Pharm. 16, 4416–4421 (2019).
Keinänen, O. et al. Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy. Proc. Natl. Acad. Sci. USA 117, 28316–28327 (2020).
Rossin, R., Lappchen, T., van den Bosch, S. M., Laforest, R. & Robillard, M. S. Diels–Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody. J. Nucl. Med. 54, 1989–1995 (2013).
Rossin, R. et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed. Engl. 49, 3375–3378 (2010).
Zeglis, B. M. et al. A pretargeted PET imaging strategy based on bioorthogonal Diels–Alder click chemistry. J. Nucl. Med. 54, 1389–1396 (2013).
Zeglis, B. M. et al. Optimization of a pretargeted strategy for the PET imaging of colorectal cancer via the modulation of radioligand pharmacokinetics. Mol. Pharm. 12, 3575–3587 (2015).
Meyer, J. P. et al. 18F-based pretargeted PET imaging based on bioorthogonal Diels–Alder click chemistry. Bioconjug. Chem. 27, 298–301 (2016).
Meyer, J. P. et al. Exploring structural parameters for pretargeting radioligand optimization. J. Med. Chem. 60, 8201–8217 (2017).
Houghton, J. L. et al. Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand Diels–Alder click chemistry. Mol. Cancer Ther. 16, 124–133 (2017).
Adumeau, P. et al. A pretargeted approach for the multimodal PET/NIRF imaging of colorectal cancer. Theranostics 6, 2267–2277 (2016).
Membreno, R., Cook, B. E., Fung, K., Lewis, J. S. & Zeglis, B. M. Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma. Mol. Pharm. 15, 1729–1734 (2018).
Poty, S. et al. Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 25, 868–880 (2019).
Membreno, R., Cook, B. E. & Zeglis, B. M. Pretargeted radioimmunotherapy based on the inverse electron demand Diels–Alder reaction. J. Vis. Exp. 2019, 10.3791/59041 (2019).
Cook, B. E., Membreno, R. & Zeglis, B. M. Dendrimer scaffold for the amplification of in vivo pretargeting ligations. Bioconjug. Chem. 29, 2734–2740 (2018).
Siegl, S. J., Galeta, J., Dzijak, R., Dracinsky, M. & Vrabel, M. Bioorthogonal fluorescence turn-on labeling based on bicyclononyne-tetrazine cycloaddition reactions that form pyridazine products. Chempluschem 84, 493–497 (2019).
Meyer, J. P. et al. Bioorthogonal masking of circulating antibody-TCO groups using tetrazine-functionalized dextran polymers. Bioconjug. Chem. 29, 538–545 (2018).
van Duijnhoven, S. M. et al. Diabody pretargeting with click chemistry in vivo. J. Nucl. Med. 56, 1422–1428 (2015).
Yazdani, A. et al. A bone-seeking trans-cyclooctene for pretargeting and bioorthogonal chemistry: a proof of concept study using 99mTc- and 177Lu-labeled tetrazines. J. Med. Chem. 59, 9381–9389 (2016).
Algar, W. R. et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug. Chem. 22, 825–858 (2011).
Lesch, H. P., Kaikkonen, M. U., Pikkarainen, J. T. & Yla-Herttuala, S. Avidin-biotin technology in targeted therapy. Expert Opin. Drug Deliv. 7, 551–564 (2010).
Paganelli, G. et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26, 348–357 (1999).
Breitz, H. B. et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med. 41, 131–140 (2000).
Schoffelen, R. et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol. Cancer Ther. 9, 1019–1027 (2010).
Goldenberg, D. M., Chatal, J. F., Barbet, J., Boerman, O. & Sharkey, R. M. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther. 2, 19–31 (2007).
Hall, H. et al. In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and 67/68Ga-labeled haptens by pretargeting. Am. J. Nucl. Med. Mol. Imaging 2, 141–150 (2012).
Bodet-Milin, C. et al. Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial. J. Nucl. Med. 57, 1505–1511 (2016).
Bodet-Milin, C. et al. Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients. Front. Med. 2, 84 (2015).
Sharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C. H. & Goldenberg, D. M. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 40, 190–203 (2010).
Liu, G. et al. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug. Chem. 22, 2539–2545 (2011).
Gupta, A., Mishra, A. & Puri, N. Peptide nucleic acids: advanced tools for biomedical applications. J. Biotechnol. 259, 148–159 (2017).
Kim, K. L. et al. Supramolecular latching system based on ultrastable synthetic binding pairs as versatile tools for protein imaging. Nat. Commun. 9, 1712 (2018).
Sundhoro, M., Jeon, S., Park, J., Ramstrom, O. & Yan, M. Perfluoroaryl azide staudinger reaction: a fast and bioorthogonal reaction. Angew. Chem. Int. Ed. Engl. 56, 12117–12121 (2017).
Agard, N. J., Prescher, J. A. & Bertozzi, C. R. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J. Am. Chem. Soc. 126, 15046–15047 (2004).
Carroll, L., Evans, H. L., Aboagye, E. O. & Spivey, A. C. Bioorthogonal chemistry for pre-targeted molecular imaging—progress and prospects. Org. Biomol. Chem. 11, 5772–5781 (2013).
Ackerman, M. E. et al. A33 antigen displays persistent surface expression. Cancer Immunol. Immunother. 57, 1017–1027 (2008).
Keinänen, O. et al. Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. EJNMMI Res. 7, 95 (2017).
Houghton, J. L. et al. Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses. J. Nucl. Med. 57, 453–459 (2016).
Rossin, R., van Duijnhoven, S. M., Lappchen, T., van den Bosch, S. M. & Robillard, M. S. Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels–Alder reaction. Mol. Pharm. 11, 3090–3096 (2014).
Royzen, M., Yap, G. P. & Fox, J. M. A photochemical synthesis of functionalized trans-cyclooctenes driven by metal complexation. J. Am. Chem. Soc. 130, 3760–3761 (2008).
Rondon, A. et al. Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models. Sci. Rep. 7, 14918 (2017).
Maggi, A. et al. Development of a novel antibody-tetrazine conjugate for bioorthogonal pretargeting. Org. Biomol. Chem. 14, 7544–7551 (2016).
Billaud, E. M. F. et al. Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels–Alder reactions. Potential applications for pretargeted in vivo PET imaging. Chem. Sci. 8, 1251–1258 (2017).
Billaud, E. M. F. et al. Pretargeted PET imaging using a bioorthogonal 18F-labeled trans-cyclooctene in an ovarian carcinoma model. Bioconjug. Chem. 28, 2915–2920 (2017).
Steen, E. J. L. et al. Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging. Bioorg. Med. Chem. Lett. 29, 986–990 (2019).
Edem, P. E. et al. Evaluation of a 68Ga-labeled DOTA-tetrazine as a PET alternative to 111In-SPECT pretargeted imaging. Molecules 25, 463 (2020).
Edem, P. E. et al. Evaluation of the inverse electron demand Diels–Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging. EJNMMI Res. 9, 49 (2019).
Keinänen, O. et al. A new highly reactive and low lipophilicity fluorine-18 labeled tetrazine derivative for pretargeted PET imaging. ACS Med. Chem. Lett. 7, 62–66 (2016).
Reiner, T., Lewis, J. S. & Zeglis, B. M. Harnessing the bioorthogonal inverse electron demand Diels–Alder cycloaddition for pretargeted PET imaging. J. Vis. Exp. 2015, e52335 (2015).
Altai, M. et al. Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting. J. Nucl. Med. 57, 431–436 (2016).
Vito, A. et al. A 99mTc-labelled tetrazine for bioorthogonal chemistry. Synthesis and biodistribution studies with small molecule trans-cyclooctene derivatives. PloS One 11, e0167425 (2016).
Zhou, Z., Devoogdt, N., Zalutsky, M. R. & Vaidyanathan, G. An efficient method for labeling single domain antibody fragments with 18F using tetrazine-trans-cyclooctene ligation and a renal brush border enzyme-cleavable linker. Bioconjug. Chem. 29, 4090–4103 (2018).
Litau, S., Seibold, U., Wangler, B., Schirrmacher, R. & Wangler, C. iEDDA conjugation reaction in radiometal labeling of peptides with 68Ga and 64Cu: unexpected findings. ACS Omega 3, 14039–14053 (2018).
Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J. & Bunn, P. A. Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77–89 (1984).
Sharma, S. K. et al. A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl. Med. Biol. 71, 32–38 (2019).

Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy

Supplementary information

Supplementary Information

推荐阅读